Consensus guidelines on anti-cardiolipin antibody testing and reporting

被引：67

作者：

Wong, RCW ^{[1
]}

Gillis, D

Adelstein, S

Baumgart, K

Favaloro, EJ

Hendle, MJ

Homes, P

Pollock, W

Smith, S

Steele, RH

Sturgess, A

Wilson, RJ

机构：

[1] Princess Alexandra Hosp, QHPS, Div Immunol, Woolloongabba, Qld 4102, Australia

[2] Royal Brisbane Hosp, Brisbane, Qld 4029, Australia

[3] Inst Med & Vet Sci, Div Human Immunol, Adelaide, SA, Australia

[4] Royal Prince Alfred Hosp, Cent Sydney Lab Serv, Dept Clin Immunol, Sydney, NSW, Australia

[5] Douglas Hanly Moir Pathol, Sydney, NSW, Australia

[6] Westmead Hosp, Inst Clin Pathol & Med Res, Dept Haematol, Westmead, NSW 2145, Australia

[7] Queensland Med Lab, Brisbane, Qld, Australia

[8] Western Diagnost Pathol, Perth, WA, Australia

[9] Gribbles Pathol, Melbourne, Vic, Australia

[10] Canterbury DHB, Christchurch, New Zealand

[11] Wellington Hosp, Wellington, New Zealand

[12] Capital Coast DHB, Wellington, New Zealand

[13] St George Hosp, Sydney, NSW, Australia

来源：

PATHOLOGY | 2004年 / 36卷 / 01期

关键词：

anti-cardiolipin; antibody; consensus; guidelines; minimum; optimum; reporting; testing;

D O I：

10.1080/00313020310001643615

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Consensus guidelines on anti-cardiolipin antibody (aCL) testing have been developed to help minimise laboratory variation in the performance and reporting of aCL assays. These guidelines include minimum, optimum and optional recommendations for the following aspects of aCL testing and reporting: (1) isotype of aCL tested; (2) specimen type; (3) controls and assay precision; (4) calibrators; (5) patient samples; (6) rheumatoid factors and IgM aCL testing; (7) reporting of results; (8) cut-off values; and (9) interpretative comments.

引用

页码：63 / 68

页数：6

共 21 条

[1] FALSE-POSITIVE TEST RESULT FOR IGM ANTICARDIOLIPIN ANTIBODY DUE TO IGM RHEUMATOID-FACTOR [J].

AGOPIAN, MS ;

BOCTOR, FN ;

PETER, JB .

ARTHRITIS AND RHEUMATISM, 1988, 31 (09) :1212-1212

[2] INTERLABORATORY INCONSISTENCIES IN DETECTION OF ANTICARDIOLIPIN ANTIBODIES [J].

COULAM, CB ;

MCINTYRE, JA ;

WAGENKNECHT, D ;

ROTE, N .

LANCET, 1990, 335 (8693) :865-865

[3] Assessing the usefulness of anticardiolipin antibody assays - A cautious approach is suggested by high variation and limited consensus in multilaboratory testing [J].

Favaloro, EJ ;

Silvestrini, R .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 118 (04) :548-557

[4] Clinical utility of anticardiolipin antibody assays: High inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach [J].

Favaloro, EJ ;

Silvestrini, R ;

Mohammed, A .

PATHOLOGY, 1999, 31 (02) :142-147

[5]

Finazzi G, 1997, HAEMATOLOGICA, V82, P101

[6]

Fontaine M, 2001, THROMB HAEMOSTASIS, V86, P1123

[7] Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature [J].

Galli, M ;

Luciani, D ;

Bertolini, G ;

Barbui, T .

BLOOD, 2003, 101 (05) :1827-1832

[8] Guidelines on the investigation and management of the antiphospholipid syndrome [J].

Greaves, M ;

Cohen, H ;

Machin, SJ ;

Mackie, I .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (04) :704-715

[9] Revisiting the anticardiolipin test and its standardization [J].

Harris, EN ;

Pierangeli, SS .

LUPUS, 2002, 11 (05) :269-275

[10]

Ichikawa K, 1999, ARTHRITIS RHEUM, V42, P2461, DOI 10.1002/1529-0131(199911)42:11<2461::AID-ANR25>3.0.CO

← 1 2 3 →